11/29/2022  5:31:51 PM Chg. +1.20 Volume Bid6:07:06 PM Ask6:07:06 PM Market Capitalization Dividend Y. P/E Ratio
191.80CHF +0.63% 10,656
Turnover: 2.05 mill.
181.00Bid Size: 160 181.00Ask Size: 20 2.43 bill.CHF 0.31% 104.81

Business description

The Ypsomed Holding AG is one of the worldwide leading independent developers and manufacturers of injection systems for self-medication and a diabetes specialist. The company offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility and other therapeutic areas. As a leader in innovation and technology, it is a preferred partner of pharmaceutical and biotech companies for pens, autoinjectors and pump systems for administering liquid medications. Ypsomed presents and markets its product portfolios under the umbrella brands mylife™ Diabetescare directly to patients or via pharmacies and hospitals as well as under YDS Ypsomed Delivery Systems in business-tobusiness operations with pharmaceutical companies.The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements; contract development and manufacturing; as well as the assembly of injection systems with medications, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide. Founded in 2003 from the wellknown company Disetronic, Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors.
 

Management board & Supervisory board

CEO
-
Management board
Niklaus Ramseier, Dr. Beat Maurer, Dr. Eberhard Bauer, Frank Mengis, Hans Ulrich Lehmann, Michael Zaugg, Simon Michel, Ulrike Bauer
Supervisory board
Betül Susamis Unaran, Dr. h.c. Willy Michel, Dr. Martin Münchbach, Gilbert Achermann, Paul Fonteyne
 

Company data

Name: Ypsomed Holding AG
Address: Brunnmattstrasse 6,CH-3401 Burgdorf
Phone: +41-34-424-4111
Fax: +41-34-424-4122
E-mail: info@ypsomed.com
Internet: www.ypsomed.com
Industry: Healthcare
Sector: Medical Products
Sub sector: Advanced Medical Devices
End of financial year: 3/31
Free Float: 25.10%
IPO date: -

Investor relations

Name: Thomas Kutt
IR phone: +41-34-424-3555
IR Fax: +41-34-424-4122
IR e-mail: thomas.kutt@ypsomed.com

Main Shareholders

Techpharma Management AG, Burgdorf - Direkt bzw. indirekte Halter Dr. h.c. Willy Michel, Simon Michel, Serge Michel, Lavinia Camilla Nussio
 
74.90%
Freefloat
 
25.10%